香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 本公告乃根據一九三三年美國證券法（經 修 訂）第135條 而 作 出。本 公 告 僅 供 參 考 之 用，並 不 構 成 亦 不 擬 作 為 在 香 港、美 國 或 其 他 地 方 收 購、購 買 或 認 購 證 券 之 邀 請 或 要 約，亦 不 構 成 出 售 證 券 之 要 約 或 招 攬 購 買 證 券 之 要 約。在 未 辦 理 登 記 手 續 或 未 獲 豁 免 登 記 規 定 的 情 況 下，不 得 在 美 國 發 售 或 出 售 證 券。本 公 告 或 其 中 所 載 任 何 內 容 均 不 構 成 任 何 合 約 或 承 諾 之 基 礎。有 關 要 約 或 邀 請 僅 可 以 刊 發 招 股 章 程 方 ...

Core Viewpoint - The company held its first extraordinary general meeting of shareholders in 2026, where a significant resolution regarding the spin-off of its subsidiary, Fosun Antigen, was discussed. The proposal to provide guaranteed allocations to A-shareholders was rejected, but the spin-off plan remains unaffected [2][10]. Meeting Details - The extraordinary general meeting was held on February 27, 2026, at Shanghai Tianxi Jiafu Puti Hotel [3]. - The total number of shares with voting rights was 2,639,554,073, including 2,098,582,573 A-shares and 540,971,500 H-shares [3]. Voting Results - The proposal to spin off Fosun Antigen to the Hong Kong Stock Exchange was approved in the general meeting, while the specific proposal to provide guaranteed allocations to A-shareholders was not approved in the A-share meeting [7][9]. - The resolutions regarding the spin-off were passed in the H-share meeting, indicating a split in shareholder support between A and H shareholders [10]. Legal Compliance - The meeting was conducted in accordance with the Company Law of the People's Republic of China and the company's articles of association, ensuring the legality of the proceedings and voting [4][11].

Core Viewpoint - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has received approval from the China Securities Regulatory Commission to publicly issue technology innovation corporate bonds totaling up to RMB 6 billion, which is valid for 24 months from the date of approval [1] Group 1: Stock Performance - As of the market close on February 27, 2026, the stock price of Fosun Pharmaceutical was CNY 26.48, down 0.11% from the previous trading day [1] - The stock opened at CNY 26.51, reached a high of CNY 26.6, and a low of CNY 26.42, with a trading volume of CNY 334 million and a turnover rate of 0.6% [1] Group 2: Bond Issuance - The company plans to issue the bonds in phases based on funding needs and market conditions, while fulfilling relevant information disclosure obligations [1]

Core Viewpoint - The first financial report of the newly independent Magnum ice cream company post-Unilever spin-off shows a significant decline in net profit, highlighting challenges in achieving growth targets amid high restructuring costs and market competition [1][2][3]. Financial Performance - Magnum's revenue for 2025 was €7.9 billion, remaining flat year-on-year, while net profit plummeted by 48.4% to €307 million from €595 million in 2024 [1][2]. - The decline in net profit is attributed to increased costs related to the spin-off (€118 million), higher financial costs (€104 million), and adverse currency fluctuations [2]. - The total cash expenditure for the spin-off reached €564 million (approximately ¥4.653 billion), which included costs for business acquisition and disposal (€196 million), organizational separation (€120.5 million), and mid-term operational implementation (€148.5 million) [2]. Market Position and Strategy - Despite the challenges, Magnum achieved organic sales growth in China, maintaining a strong market share [1][3]. - The company plans to focus on low-sugar and plant-based product innovations, enhance localization efforts in China, and consider acquisitions of local or unique brands in China and Europe/America to expand its business [1][3][4]. - In the first half of 2025, revenue from the Chinese market reached €270 million, reflecting double-digit growth, with plans to launch nearly 30 new products [4]. Challenges and Competitive Landscape - Magnum faces intense competition from local brands like Yili and Mengniu, which dominate the lower-tier market with established distribution channels [4][6]. - The company’s profitability in Europe and Australia/New Zealand has been impacted by rising raw material costs, particularly cocoa [3]. - The anticipated adjusted EBITDA margin for 2025 is expected to decrease from 16.8% to approximately 16% due to lower sales and profit margins [3]. Future Outlook - The company aims to strengthen product innovation and expand consumption scenarios while promoting premium brands globally [5]. - In the AMEA region, Magnum plans to enhance freezer placements and improve distribution in countries like Indonesia and the Philippines [6]. - The management previously indicated a target of 5% growth post-spin-off, but this goal may be postponed beyond 2026, necessitating proof of the spin-off's strategic validity through performance [6].

Core Viewpoint - Yanzhou Coal Mining Company Limited (兖矿能源) announced the proposed spin-off of its subsidiary, Kason Technology Co., Ltd. (卡松科技), to be listed on the National Equities Exchange and Quotations (新三板) [1] Group 1 - The company has submitted an application for the proposed spin-off to the Hong Kong Stock Exchange (香港联交所) [1] - The board of directors has received approval from the Hong Kong Stock Exchange under the Listing Rules, specifically the "Application Guidance No. 15" [1] - The company has obtained a letter of consent from the National Equities Exchange and Quotations Co., Ltd. (全国中小企业股份转让系统有限责任公司) for the public transfer and listing of Kason Technology's shares [1]

Core Viewpoint - The company, Sihuan Pharmaceutical (00460), has announced a positive earnings forecast, expecting revenue of at least 2.5 billion RMB for the year ending December 31, 2025, representing a growth rate of over 30% compared to the previous year [1][5]. Group 1: Financial Performance - The company anticipates a net profit of no less than 150 million RMB for the same period [1][5]. - The growth in performance is primarily driven by the rapid expansion of the medical aesthetics business, which is expected to generate over 1.4 billion RMB in revenue and over 700 million RMB in segment profit, with both metrics showing an annual growth rate exceeding 90% [1][5]. Group 2: Business Segments - The medical aesthetics segment has become the largest contributor to both revenue and profit for the company, significantly boosting overall performance [1][5]. - The innovative drug business is entering a harvest phase, which is expected to improve the company's profit structure [1][5]. Group 3: Financial Health - The company maintains a robust financial position with ample cash reserves, having conducted multiple rounds of share buybacks and completed the spin-off of Xuan Bamboo Biotechnology, which has optimized the financial structure and driven profit breakthroughs [1][5].

Core Viewpoint - Four Seasons Pharmaceutical (00460) anticipates significant revenue growth, projecting at least 2.5 billion RMB in revenue and 150 million RMB in net profit for the fiscal year ending December 31, 2025, driven primarily by its aesthetic medicine business and innovative drug segment [1] Group 1: Financial Performance - The company expects revenue growth of over 30% compared to the same period last year, with a minimum revenue target of 2.5 billion RMB [1] - Net profit is projected to be no less than 150 million RMB for the same period [1] Group 2: Business Segments - The aesthetic medicine segment is expected to generate over 1.4 billion RMB in revenue and over 700 million RMB in segment profit, with both metrics showing an annual growth rate exceeding 90% [1] - The innovative drug business is entering a harvest phase, significantly improving the company's profit structure [1] Group 3: Financial Health - The company maintains a robust financial position with ample cash reserves [1] - Multiple rounds of share buybacks have been implemented, and the successful spin-off of Xuan Bamboo Biotechnology has optimized the company's financial structure, contributing to profit breakthroughs [1]

Spin-off and Listing - Weisheng Group (03393.HK) plans to spin off Weisheng Information Technology for independent listing on the Sci-Tech Innovation Board [1] Resumption and Suspension - Huaneng International (01102.HK) terminates previous subscription agreement and plans to issue 1.8 billion shares at a 19% discount to Shuncheng International, resuming trading on April 8 [1] Earnings Forecast - Zoomlion Heavy Industry (01157.HK) expects a net profit increase of 125.61%-178.69% to between 850 million and 1.05 billion yuan for the first quarter [1] - VTech Holdings (00303.HK) anticipates a 15%-20% decline in net profit for the fiscal year 2019 due to lower-than-expected sales of telecommunications products in the second half [1] - Changhong Jiahua (08016.HK) forecasts a net profit increase of over 50% for the first quarter [1] - MINDTELL TECH (08611.HK) expects a 51.7% decline in profit for the first quarter [1] Operational Data - China Overseas Development (00688.HK) reports first-quarter sales of 79.536 billion HKD, a year-on-year increase of 21% [1] - Agile Group (03383.HK) records a first-quarter pre-sale amount of 25.08 billion yuan, up 18.4% year-on-year [1] - Greentown China (03900.HK) sees total contract sales drop by 8.6% to 25.5 billion yuan from January to March [1] - Longfor Properties (03380.HK) reports a 7% increase in contract sales to 17.01 billion yuan for the first quarter [1] - Times China Holdings (01233.HK) achieves contract sales of 13.97 billion yuan in the first quarter [1] - First Creation Properties (02868.HK) records a signing amount of 13.91 billion yuan, a year-on-year increase of 63.2% [1] - Jianye Real Estate (00832.HK) reports first-quarter sales of 12.836 billion yuan, up 69.8% year-on-year [1] - China Overseas Hongyang Group (00081.HK) sees a 3.38% increase in contract sales to 9.444 billion HKD for the first quarter [1] - Yincheng International Holdings (01902.HK) achieves total contract sales of 2.023 billion yuan in the first quarter [1] - Fantasia Holdings (01777.HK) reports March sales growth of 26.23% to 1.92 billion yuan [1] - Xinli International (00732.HK) sees a 12.5% increase in comprehensive operating net income to 4.072 billion HKD for the first quarter [1] - Hysun Engineering (02236.HK) reports new contract total value of 7.226 billion yuan for the first quarter, with uncompleted contract total value of 19.467 billion yuan [1] - Sunshine 100 China (02608.HK) achieves contract sales of 1.358 billion yuan in the first quarter [1] - Hengding Industrial (01393.HK) reports a decline of 18% in raw coal production to 458,000 tons for the first quarter [1] Mergers and Acquisitions - Rundong Auto (01365.HK) plans to sell a company operating 56 car dealerships for 3.4 billion yuan [1] - China Overseas Development (00688.HK) spends 7.726 billion yuan to acquire five land parcels in March [1] - Greenland Hong Kong (00337.HK) subsidiary sells 100% equity of a property development company, valued at no less than 2.8 billion yuan [1] - Longfor Green Group (00106.HK) plans to repurchase 49% equity of Suzhou Longhong Real Estate for 173 million yuan [1] Equity Financing - Vanke Enterprises (02202.HK) successfully issues approximately 263 million new H-shares, netting 7.78 billion HKD [2] - Ronshine China (03301.HK) plans to place up to 108 million shares to optimize shareholder structure [2] - Aoyuan Health (03662.HK) issues 26.25 million shares at a 19.56% discount due to the exercise of over-allotment rights [2] Major Events - Genscript (01548.HK) receives priority review designation from EMA for Janssen's JNJ-4528 drug [2] - Xun'an Technology (01647.HK) joint venture with Longma Bio obtains industrial hemp business qualification [2] - Haosha International (02200.HK) denies all allegations from Bonitas, claiming lack of professional understanding of its business model [2] - Kangzhe Pharmaceutical (00867.HK) extends exclusive promotion rights for New Vitality and Immodium until December 31, 2021 [2] - Weinan Group (01608.HK) secures its first distributed generation project in Sri Lanka [2] - Xinhua Pharmaceutical (00719.HK) completes transfer registration for proposed transfer, with Hualu Holdings becoming the direct controlling shareholder [2] - Zhejiang United Investment (08366.HK) plans to partner with Hengji to develop special equipment based on 5G network technology [2] - Tongfang Kontrol (01312.HK) sells 21% equity in Tongfang to China Nuclear Capital [2] - Alibaba Pictures (01060.HK) subsidiary signs a framework agreement for entertainment work cooperation with AGH [2] - Kingsoft (03888.HK) announces a framework agreement with Xiaomi to provide hardware products [2] - Binhai Services (03316.HK) partially exercises over-allotment rights as the price stabilization period ends [2]

Group 1 - Weisheng Holdings (03393) saw a nearly 6% increase in early trading, reaching HKD 24.48 with a transaction volume of HKD 35.6 million [1] - The company announced plans to spin off Weiyuan Energy for independent listing on the Hong Kong Stock Exchange, following the introduction of strategic investor Boyu Capital [1] - Boyu Capital will invest a total of RMB 380 million to subscribe for 48.81 million new shares of Weiyuan Energy, representing approximately 8% of its expanded share capital, with Weiyuan Energy valued at around RMB 4.75 billion [1] Group 2 - Guotou Securities (International) released a report anticipating collaboration between Weiyuan Energy and Boyu Capital, leveraging Boyu's extensive experience in data centers, technology, and new energy sectors to enhance business expansion and market competitiveness [1] - The strong demand for Weisheng Holdings' ADO business in data centers is entering a rapid growth phase, becoming a significant driver of overall business growth for the group [1]

Group 1 - The core viewpoint of the article is that Weisheng Holdings (03393) is experiencing a significant stock price increase following the announcement of the proposed spin-off of Weiyuan Energy for independent listing on the Hong Kong Stock Exchange [1] - Weiyuan Energy has introduced strategic investor Boyu Capital, which will invest a total of RMB 380 million to subscribe for 48.81 million new shares, representing approximately 8% of the enlarged share capital, with Weiyuan Energy's valuation estimated at around RMB 4.75 billion [1] - Guotai Junan Securities (International) anticipates that Weiyuan Energy will collaborate with Boyu Capital to leverage its extensive resources in data centers, technology, and new energy sectors, which is expected to enhance the company's business expansion and market competitiveness [1] Group 2 - Weisheng Holdings' ADO business is entering a rapid growth phase due to strong demand in data centers, becoming a significant driver of overall business growth for the group [1]